Respiratory insufficiency in postmenopausal women: Sustained improvement of gas exchange with short-term medroxyprogesterone acetate

Chest

Volumn 115, Issue 6, 1999, Pages 1581-1587

  Saaresranta, Tarja ^a   Polo Kantola, Päivi ^a   Irjala, Kerttu ^a   Helenius, Hans ^b   Polo, Olli ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b Universität Turku   (Finland)

Author keywords

COPD; Hypercapnia; Hypoxemia; Medroxyprogesterone acetate; Menopause; Respiratory stimulant; Sustained effect; Women

Indexed keywords

BICARBONATE; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; AGED; ALKALOSIS; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL OXYGEN TENSION; ARTICLE; BLEEDING; CHRONIC RESPIRATORY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GAS EXCHANGE; HORMONE SUBSTITUTION; HUMAN; HYPERCAPNIA; HYPOXEMIA; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0033028888     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.6.1581     Document Type: Article

References (32)

1. 1 Shneerson JM. The changing role of mechanical ventilation in COPD. Eur Respir J 1996; 9:393-398
2. 2 Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): a consensus statement of the European Respiratory Society (ERS). Eur Respir J 1995; 8:1398-1420
3. 3 Celli BR, Snider GL, Heffner J, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:S77-S120
4. 4 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93:391-398
5. 5 Medical Research Council Working Party. Long-term domiciliary oxygen in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1:681-686
6. 6 Cullen JH, Brum VC, Reidt WU. The respiratory effects of progesterone in severe pulmonary emphysema. Am J Med 1959; 27:551-557
7. 7 Tyler JM. The effect of progesterone on the respiration of patients with emphysema and hypercapnia. J Clin Invest 1960; 39:34-41
8. 8 Skatrud JB, Dempsey JA, Bhansali P, et al. Determinants of chronic carbon dioxide retention and its correction in humans. J Clin Invest 1980; 65:813-821
9. 2 retention during sleep in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1981; 124:260-268
10. 10 Skatrud JB, Dempsey JA. Relative effectiveness of acetazolamide versus medroxyprogesterone acetate in correction of chronic carbon dioxide retention. Am Rev Respir Dis 1983; 127:405-412
11. 11 Dolly FR, Block AJ. Medroxyprogesterone acetate and COPD: effect on breathing and oxygenation in sleeping and awake patients. Chest 1983; 84:394-398
12. 12 Delaunois L, Delwiche JP, Lulling J. Effect of medroxyprogesterone on ventilatory control and pulmonary gas exchange in chronic obstructive patients. Respiration 1985; 47:107-113
13. 13 al-Damluji S. The effect of ventilatory stimulation with medroxyprogesterone on exercise performance and the sensation of dyspnoea in hypercapnic chronic bronchitis. Br J Dis Chest 1986; 80:273-279
14. 14 Morrison DA, Goldman AL. Oral progesterone treatment in chronic obstructive lung disease: failure of voluntary hyperventilation to predict response. Thorax 1986; 41:616-619
15. 15 Daskalopoulou E, Patakas D, Tsara V, et al. Comparison of almitrine bismesylate and medroxyprogesterone acetate on oxygenation during wakefulness and sleep in patients with chronic obstructive lung disease. Thorax 1990; 45:666-669
16. 16 Skatrud JB, Dempsey JA, Kaiser DG. Ventilatory responses to medroxyprogesterone acetate in normal subjects: time course and mechanism. J Appl Physiol 1978; 44:939-944
17. 17 Johansson EDB, Johansen PB, Rasmussen SN. Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. Acta Pharmacol Toxicol 1986; 58: 311-317
18. 18 Lyons HA, Huang CT. Therapeutic use of progesterone in alveolar hypoventilation associated with obesity. Am J Med 1968; 44:881-888
19. 19 Saaresranta T, Polo-Kantola P, Aittokallio T, et al. Prolonged improvement with short-term progesterone in postmenopausal women with nocturnal hypercapnia [abstract]. Am J Respir Crit Care Med 1998; 157:A57
20. 20 Leavitt WW, Blaha GC. An estrogen-stimulated, progesterone-binding system in the hamster uterus and vagina. Steroids 1972; 19:263-274
21. 21 Brodeur P, Mockus M, McCullough R, et al. Progesterone receptors and ventilatory stimulation by progestin. J Appl Physiol 1986; 60:590-595
22. 22 Goodland RL, Reynolds JG, McCoord AB, et al. Respiratory and electrolyte effects induced by estrogen and progesterone. Fertil Steril 1953; 4:300-316
23. 23 Sadoff L, Lusk W. The effect of large doses of medroxyprogesterone acetate (MPA) on urinary estrogen levels and serum levels of cortisol, T4, LH and testosterone in patients with advanced cancer. Obstet Gynecol 1974; 43:262-267
24. 24 Kryger MH, McCullough RE, Collins D, et al. Treatment of excessive polycythemia of high altitude with respiratory stimulant drugs. Am Rev Respir Dis 1978; 117:455-464
25. 25 Saarni HU, Rautio A, Kärki NT, et al. Disposition of medroxyprogesterone acetate and drug metabolism activity. Res Commun Chem Pathol Pharmacol 1983; 39:251-260
26. 26 Zwillich CW, Natalino MR, Sutton FD, et al. Effects of progesterone on chemosensitivity in normal men. J Lab Clin Med 1978; 92:262-269
27. 27 Hannhart B, Pickett CK, Moore LG. Effects of estrogen and progesterone on carotid body neural output responsiveness to hypoxia. J Appl Physiol 1990; 68:1909-1916
28. 28 Regensteiner JG, Hiatt WR, Byyny RL, et al. Short-term effects of estrogen and progestin on blood pressure of normotensive postmenopausal women. J Clin Pharmacol 1991; 31:543-548
29. 29 Prelevic GM, Beljic T. The effect of oestrogen and progestogen replacement therapy on systolic flow velocity in healthy postmenopausal women. Maturitas 1994; 20:37-44
30. 30 Hortobagyi GN, Buzdar AU, Frye D, et al. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat 1985; 5:321-326
31. 31 Khoo S-K, Coglan MJ, Wright GR, et al. Hormone therapy in women in the menopause transition: randomised, double-blind, placebo-controlled trial of effects on body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium. Med J Aust 1998; 168:216-220
32. 32 Edwards N, Wilcox I, Polo OJ, et al. Hypercapnic blood pressure response is greater during the luteal phase of the menstrual cycle. J Appl Physiol 1996; 81:2142-2146